ArticleCurrent oncology (Toronto, Ont.)2022
The Impact of Organised Screening Programs on Breast Cancer Stage at Diagnosis for Canadian Women Aged 40-49 and 50-59.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline.Systematic reviews · 2024Pooled it
- Enhancing the OncoSim-Breast model using Canadian breast density information.Health reports · 2026Article
- Impact of Method of Detection of Breast Cancer on Clinical Outcomes in Individuals Aged 40 Years or Older.Radiology. Imaging cancer · 2025Observational
- 4D Dynamic contrast-enhanced breast CT: Phantom-based reconstruction parameter optimization for iodine quantification.Medical physics · 2025Article
- Breast cancer patients enrolled in the Swiss mammography screening program "donna" demonstrate prolonged survival.Breast cancer research : BCR · 2024Article
- The Canadian Breast Cancer Symposium 2023 Meeting Report.Current oncology (Toronto, Ont.) · 2024Article
- Insights into the Refusal of Free Screening Mammograms: Exploring Contributing Factors.Breast cancer (Dove Medical Press) · 2024Article
- Linking African ancestral substructure to prostate cancer health disparities.Scientific reports · 2023Article
- Impact of Breast Cancer Screening on 10-Year Net Survival in Canadian Women Age 40-49 Years.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing.Current oncology (Toronto, Ont.) · 2023Article
- Progress and Remaining Gaps in the Early Detection and Treatment of Breast Cancer.Current oncology (Toronto, Ont.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between Canadian mammography screening practices for women 40−49 and breast cancer (BC) stage at diagnosis in women 40−49 and 50−59 years was assessed using data from the Canadian Cancer Registry, provincial/territorial screening practices, and screening information from the Canadian Community Health Survey. For the 2010 to 2017 period, women aged 40−49 were diagnosed with lesser relative proportions of stage I BC (35.7 vs. 45.3%; p < 0.001), but greater proportions of stage II (42.6 vs. 36.7%, p < 0.001) and III (17.3 vs. 13.1%, p < 0.001) compared to women 50−59. Stage IV was lower among women 40−49 than 50−59 (4.4% vs. 4.8%, p = 0.005). Jurisdictions with organised screening programs for women 40−49 with annual recall (screeners) were compared with those without (comparators). Women aged 40−49 in comparator jurisdictions had higher proportions of stages II (43.7% vs. 40.7%, p < 0.001), III (18.3% vs. 15.6%, p < 0.001) and IV (4.6% vs. 3.9%, p = 0.001) compared to their peers in screener jurisdictions. Based on screening practices for women aged 40−49, women aged 50−59 had higher proportions of stages II (37.2% vs. 36.0%, p = 0.003) and III (13.6% vs. 12.3%, p < 0.001) in the comparator versus screener groups. The results of this study can be used to reassess the optimum lower age for BC screening in Canada.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.